Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer

The Oncologist
Kathleen Van AstenPatrick Neven

Abstract

In estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER-2) negative breast cancers, the progesterone receptor (PR) is an independent prognostic marker. Little is known about the prognostic value of PR by tumor grade. We assessed this in two independent datasets. Women with primary operable, invasive ER+ HER-2 negative breast cancer diagnosed between 2000 and 2012, treated at University Hospitals Leuven, were included. We assessed the association of PR status and subtype (grade 1-2 vs. grade 3) with distant recurrence-free interval (DRFI) and breast cancer-specific survival. The interaction between PR status and subtype was investigated, and associations of PR status by subtype were calculated. The BIG 1-98 data set was used for validation. In total, 4,228 patients from Leuven and 5,419 from BIG 1-98 were analyzed. In the Leuven cohort, the adjusted hazard ratio (HR) of PR-positive versus PR-negative tumors for DRFI was 0.66 (95% confidence interval [CI], 0.50-0.89). For the interaction with subtype (p = .34), the HR of PR status was 0.79 (95% CI, 0.61-1.01) in luminal A-like and 0.59 (95% CI, 0.46-0.76) in luminal B-like tumors. In luminal A-like tumors, observed 5-year cumulative incidences of distan...Continue Reading

References

Aug 28, 1986·The New England Journal of Medicine·H O AdamiB Stone
Oct 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G M ClarkW L McGuire
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S RomainH Magdelenat
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valerie-Jeanne BardouGary M Clark
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Jan 4, 2008·Histopathology·S J L PayneC A Wells
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leen De MaeyerPatrick Neven
Apr 22, 2008·Breast Cancer Research and Treatment·Chad J CreightonRachel Schiff
May 14, 2009·Journal of the National Cancer Institute·Maggie C U CheangTorsten O Nielsen
Aug 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vanya Van BellePatrick Neven
Apr 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O BrouckaertP Neven
Jun 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen K ChiaTorsten O Nielsen
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aleix PratCharles M Perou
Feb 15, 2013·Expert Review of Anticancer Therapy·Christos Markopoulos
Mar 19, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Molly E KleinRohit Bhargava
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Jan 26, 2016·Hematology/oncology and Stem Cell Therapy·Lubna N ChaudharyChristopher R Chitambar
Feb 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay N HarrisUNKNOWN American Society of Clinical Oncology
Dec 9, 2016·Breast Cancer Research and Treatment·Anne A EatonMahmoud El-Tamer
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyun-Seok KimLeslie Cope
Mar 1, 2017·Breast Cancer Research and Treatment·Amila OrucevicRobert E Heidel
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG

❮ Previous
Next ❯

Citations

Apr 6, 2019·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Verena Theis, Carsten Theiss
Oct 9, 2019·Breast Cancer Research and Treatment·Ki-Tae HwangSu-Jin Kim
Feb 10, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Laurence SlembrouckGiuseppe Floris
Feb 26, 2021·Cancer Management and Research·Xuemei XingZheng Liu
Dec 21, 2020·Clinical Breast Cancer·Camille KopettiOlivier Bauquis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Steroid Biochemistry and Molecular Biology
J D GrahamC L Clarke
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
David M W CorkAlison J Tyson-Capper
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hyun-Jung KimAdrian V Lee
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu
Zhao-Sheng LiYun-Tao Xie
© 2022 Meta ULC. All rights reserved